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Background: To create an arc therapy plan, certain current general calculation algorithms such as pencil-beam
calculation (PBC) are based on discretizing the continuous arc into multiple fields to simulate an arc. The iPlan
RT™ treatment planning system incorporates not only a PBC algorithm, but also a more recent Monte Carlo calculation
(MCC) algorithm that does not need beam discretization. The objective of this study is to evaluate the dose differences
in a homogenous phantom between PBC and MCC by using a three-dimensional (3D) diode array detector
(ArcCHECK™) and 3DVH software.
Methods: A cylindrically shaped ‘target’ region of interest (ROI) and a ‘periphery ROI’ surrounding the target
were designed. An arc therapy plan was created to deliver 600 cGy to the target within a 350° rotation angle,
calculated using the PBC and MCC algorithms. The radiation doses were measured by the ArcCHECK, and
reproduced by the 3DVH software. Through this process, we could compare the accuracy of both algorithms
with regard to the 3D gamma passing rate (for the entire area and for each ROI).
Results: Comparing the PBC and MCC planned dose distributions directly, the 3D gamma passing rates for the
entire area were 97.7% with the gamma 3%/3 mm criterion. Comparing the planned dose to the measured
dose, the 3D gamma passing rates were 98.8% under the PBC algorithm and 100% under the MCC algorithm.
The difference was statistically significant (p = 0.034). Furthermore the gamma passing rate decreases 7.5% in
the PBC when using the 2%/2 mm criterion compared to only a 0.4% decrease under the MCC. Each ROI as
well as the entire area showed statistically significant higher gamma passing rates under the MCC algorithm.
The failure points that did not satisfy the gamma criteria showed a regular pattern repeated every 10°.
Conclusions: MCC showed better accuracy than the PBC of the iPlan RT in calculating the dose distribution in
arc therapy, which was validated with the ArcCHECK and the 3DVH software. This may suggest that the arc
step of 10° is too large in the PBC algorithm in the iPlan RT.
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Rotational arc radiation therapy has attracted great interest
in the modern radiation therapy era. Several techniques
such as dynamic arc therapy, intensity-modulated arc ther-
apy (IMAT), volumetric arc therapy (VMAT) and helical
tomotherapy have been developed [1-3]. These techniques
are currently used widely, especially in prostate, head
and neck, and brain tumors [4]. As the technique of
rotational arc therapy advances, more precise and con-
formal radiation dose delivery has become possible. How-
ever regardless of how the radiation therapy machine
delivers conformal doses, the accuracy of the planning
algorithm and quality assurance (QA) should be an
essential prerequisite.
Classically, to calculate the dose distribution of an arc
therapy plan, most treatment planning systems (TPS)
discretize the continuous arc, thereby effectively using
several beams to simulate an arc. For example, to calcu-
late a 180° arc, the pencil-beam calculation (PBC) algo-
rithm of iPlan RT™ (BrainLAB, Heimstetten, Germany)
planning system uses 19 beams, which are each separated
from neighboring beams by a beam angle of 10°. This
method is not continuous, and it is sometimes necessary
to increase the number of beams to improve the accuracy
of the dose distribution [5]. On the other hand, the accur-
acy of the Monte Carlo dose calculation (MCC) method
depends on the number of simulated histories rather than
the number of beams. Therefore, the MCC method will
be more accurate than current TPSs for arc therapy [6].
In spite of the many reports that have been published
to show the superior accuracy of the MCC method with
respect to that of other methods [5-10], several studies
comparing the accuracy of the PBC and MCC methods
for arc therapy have not shown the possible errors that
can result from discretizing the continuous arc, and have
only focused on the errors occurring in the inhomo-
geneous condition. Using both homogeneous and in-
homogeneous phantoms, Chow et al. compared the PBC,
collapsed cone convolution (CCC), and MCC (EGS4-
based DOSXYZ code) of the Theraplan Plus™ (MDS
Nordian, Ottawa, Canada) TPS when they are applied in
arc therapy [5]. For homogenous phantoms, the PBC-
measured and CCC-measured doses agreed well (~2%
dose error) with predictions of the MCC and the TPS
planned dose. However, for the dose distribution in the
inhomogeneous phantom, only the MCC agreed well
with measurements within a 2% error, while the PBC
and CCC either underestimated or overestimated the
dose. Petoukhova et al. also compared the PBC with the
MCC of iPlan RT both in homogenous and inhomogen-
eous phantoms for conformal radiotherapy, IMRT, and
dynamic arc therapy [6]. They also concluded that the
PBC and MCC results agreed well with the measured
dose in homogenous phantoms, but not with that ininhomogeneous phantoms. The commonality of these
studies is that they only measured the delivered dose with
1) an ion-chamber or 2) a film and a 2D diode array detector.
There are plenty of QA methods for evaluating the
dosimetric accuracy of arc therapy such as gel dosimetry,
film dosimetry and diode array detectors [11,12]. The
diode array detector has been used by a number of insti-
tutions because it can be performed relatively quickly
and easily, and because it is able to measure each beam.
Recently, novel three-dimensional (3D) diode array
detectors have emerged to overcome the limitation of
existing two-dimensional (2D) detectors which can miss a
large fraction of the lateral beams because of their individ-
ual planar design [1,12]. This disadvantage of 2D detectors
can be maximized in arc therapy. Delta4 (Scandidos,
Uppsala, Sweden) and ArcCHECK (SunNuclear, Melbourne,
FL, USA) are representative examples of 3D detectors and
are commonly used in IMRTand arc therapy QA [1,12-14].
In spite of the advancement of delivery QA devices,
describing and interpreting the QA result is still difficult.
The most commonly used concept for determining whether
the measured result is appropriate is gamma analysis,
which uses two concepts: dose difference and distance-
to-agreement (DTA) [15]. The rate that satisfies a gamma
criterion is called the gamma passing rate. Although,
several gamma criteria and acceptance levels have been
used, a 3%/3 mm criterion and a 90% acceptance level
are commonly recommended in planar dosimetry, as
suggested by AAPM Task Group 119 [16]. However, the
clinical significance of the criteria for this assessment is
not clear. A higher gamma passing rate does not always
ensure safe radiation treatment. The magnitude and
location of the dose error are also very important.
The commercially available 3DVH software program
(SunNuclear) can overcome some of the disadvantages
of the planar gamma analysis concepts. With the aid of
this software, the full 3D dose distribution can be recon-
structed based on the measured data, and it can be
compared to the TPS planning dose. In addition, a
dose-volume histogram (DVH) for each target and each
region of interests (ROI) can be drawn [17,18].
In this study, we evaluated the accuracy of the MCC
and the PBC algorithm of the iPlan RT software in arc
therapy by using a 3D volumetric diode array detector
and the 3DVH software. We used a homogenous phan-
tom to focus on the dose differences that will occur by
discretizing a continuous arc. We compared not only
the 3D gamma passing rate but also several DVH-based
parameters of the MCC to those of the PBC.
Methods
Treatment design and planning
First we designed a simple radiation treatment plan to
evaluate not only the target dose but also the peripheral
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(provided by SunNuclear) with the same characteristics
(cylindrical shape, diameter: 26.5 cm, length: 27.0 cm) as
those of ArcCHECK were used. This CT set included
165 images at a slice thickness of 1.25 mm.
Two ROIs were designed. A circle with a 5 cm diameter
was contoured with an isocenter as the center of the
axial CT image, and it was named the “target ROI”. The
height of the target ROI was also 5 cm, so the target had
a cylindrical shape. Another ROI was designed, which
was named the “periphery ROI”. It is a donut-shaped
ROI on the axial CT image with a 21.5 cm thickness,
which is made by taking a circle with a 26.5 cm diameter
and then excluding the target ROI. The height of the
periphery ROI was 10 cm, so it was a circle of 26.5 cm
diameter on the axial CT image in which the target
ROI does not exist. The axial and coronal images of
these ROIs are shown in Figure 1. The volume of the
target and periphery ROIs were 106.9 cc and 5432.1 cc,
respectively.
For this study, we used iPlan RT™ (version 4.1.2,
BrainLAB). We prescribed 600 cGy to 95% of the target
ROI. The multi-leaf collimator (MLC) margins were
set to 3 mm from the target in the beams-eye-view. A
dynamic conformal arc with a rotation angle of 350°Figure 1 Axial and coronal images of the ‘target ROI and the ‘periphe(from 185° to 175°) in the clockwise direction was used
as the treatment mode.
The plan was calculated using both a PBC algorithm
and a MCC algorithm. The iPlan RT itself provides both
a PBC and MCC algorithm. The PBCs were performed
with an arc step of 10°. After the plan using the PBC al-
gorithm had been completed, this plan was recalculated
by applying the MCC algorithm. The commercial MCC
algorithm in iPlan RT is based on XVMC (X-ray voxel
Monte Carlo) code developed by Kawrakow et al. and
Fippel [19,20]. The MCC algorithm in iPlan RT has
been validated by Petoukhova et al. and Fragoso et al.
[6,10]. The dose calculation resolution was 1 mm for
both algorithms. The mean variance which estimates
the statistical uncertainty of the MCC was set to 2%.
The dose result type and the MLC modeling type were
chosen as ‘dose to medium’ and ‘accuracy optimized’.
Whether the plan was calculated by PBC and MCC al-
gorithm, the radiation that is actually delivered is same.
After the completion of both PBC and MCC calcula-
tion, we compared the dose distributions between both
algorithms, with the aid of 3DVH software. The global
gamma passing rates were analyzed with 3%/3 mm and
2%/2 mm gamma criteria and a threshold of 5% of the
maximal dose. We used the gamma passing rates for thery ROI.
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support use of a simple dose difference criterion (such as
a 3%/0 mm criterion), and also to allow the dose errors to
be more easily compared by applying the same criteria.
Dose delivery and verification with ArcCHECK
All tests were carried out with a Novalis™ (BrainLAB,
Heimstetten, Germany, and Varian Medical Systems,
Palo Alto, CA) accelerator with a 6 MV X-ray energy
and a micro-MLC.
The delivered dose was measured with ArcCHECK
which is a cylindrical acrylic 3D diode array detector. It
contains 1386 diodes in a helical arrangement at inter-
vals of 10 mm and with a diameter of 21 cm. The phys-
ical depth of each diode is 2.9 cm. The ArcCHECK
was calibrated with an absolute dose of 200 cGy with
10 × 10 cm2 field size at gantry angle 0° before this
study. The ArcCHECK has a central cavity into which
various detectors can be plugged. An EXRADIN A16-
micro ion-chamber (Standard Imaging, Middleton, WI,
USA) was inserted in an acryl insert (CavityPlug™) that
can directly measure the isocenter dose. The isocenter
dose was measured with a SUPERMAX electrometer
(Standard Imaging). During this whole study, the
ArcCHECK was operated with the plug and the ion-
chamber inside. All measurements were repeated three
times sequentially.
First, we analyzed the 2D gamma passing rates at the
level of diodes. For this analysis, a SNC Patient™ (v.6.1.1,
SunNuclear) software program was used. A digital im-
aging and communications in medicine (DICOM) dose
file of the treatment plan is imported in this software
and the dose corresponding to diode detector locations
is extracted for comparing the calculated dose to measured
dose. With this software, we obtained the gamma passing
rate of each plan at the level of diodes. We analyzed the
‘global’ gamma passing rate in which the percentage dose
difference is calculated relative to the maximum dose in
the measurement plane. Two gamma criteria, 3%/3 mm
and 2%/2 mm, were used with a threshold of 5% of the
maximal dose.
Analysis of 3D gamma passing rate with 3DVH
The doses measured using the ArcCHECK diodes were
imported into the 3DVH software along with four other
DICOM files from the TPS: the treatment plan, the CT
images, the outlined structures, and the planned dose
files. The 3DVH software can calculate the discrepancies
between the planned dose and the measured planar dose
distributions, and then translate the discrepancies to the
calculated dose of the patient. We will refer to the
resulting calculated dose of the patient as the ‘estimated
dose’. This process is done using an algorithm called
‘planned dose perturbation’ or PDP™. Before comparingthe planned and measured doses, interpolation is needed
to calculate the dose between the diodes because of the
sparse diode arrangement. This interpolation process is
referred to by the developers as ‘Smaterpolation’. The
3DVH software compares the estimated dose with the
planned dose, and calculates the 3D gamma passing
rate not only for the whole volume but also for each of
the corresponding ROIs. Further details and validation
of the 3DVH software are explained in Refs.18, 21, and
22 [18,21,22].
In our study, the estimated doses by the 3DVH soft-
ware are represented by ion chamber correction doses,
which are corrected by the ratio between the ion-chamber
measured isocenter dose and isocenter dose estimated by
3DVH based on diode measurements. The plan doses
calculated using the PBC and the MCC were compared
to the corresponding estimated dose respectively, and
the 3D gamma passing rate of each ROI was calculated.
For this 3D gamma analysis, the global gamma indices
were calculated with two gamma criteria (3%/3 mm
and 2%/2 mm) with a threshold of 5% of the global
maximal dose.
The gamma passing rate of the PBC and MCC were
compared and the difference was analyzed using the
Mann–Whitney U-test. The statistical analysis was per-
formed using STATA/IC ver.12 software (StataCorp,
College Station, TX, USA).
Comparison of DVH-based parameters
A great advantage of the 3DVH software is that various
DVH-based parameters can be estimated for all ROI
structures. Several parameters are calculated based on
the measured data, and they can be compared to the same
parameters in the plan. During this process, we can see
how the discrepancies of the planned and measured data
(e.g. the gamma passing rate) influence the clinical param-
eters (e.g. the maximal dose and mean dose). We obtained
six parameters for each ROI and for the entire plan: max-
imal dose, mean dose, the dose covering 99% of the vol-
ume (D99), the dose covering 90% of the volume (D90),
the dose covering 50% of the volume (D50) and the dose
covering 1% of the volume (D1). For each parameter,
the dose deviation (%) expressed as an absolute value,
was calculated using the following formula.




Reference study with static beams
Before evaluating the rotational arc therapy, we performed
a reference study with parallel-opposing static beams. The
Table 1 3D global gamma analysis of the reference plan
with static beams
Gamma 3%/3 mm
Gamma passing rate (%)
p value
PBC MCC
Target ROI 100 ± 0.00 100 ± 0.00 1.000
Periphery ROI 98.00 ± 0.10 99.70 ± 0.00 0.037
Entire area 98.10 ± 0.10 99.70 ± 0.00 0.034
Gamma 2%/2 mm PBC MCC p value
Target ROI 100 ± 0.00 100 ± 0.00 1.000
Periphery ROI 94.20 ± 0.30 97.77 ± 0.12 0.046
Entire area 94.47 ± 0.31 97.90 ± 0.10 0.050
Abbreviations: PBC Pencil-beam calculation, MCC Monte Carlo calculation.
Two gamma criteria (3%/3 mm and 2%/2 mm) with a threshold of 5% of
maximal dose were used. The 3D gamma passing rate of the entire area and
of each region of interest (target and periphery ROI) obtained through the
pencil-beam calculation (PBC) are compared with those obtained through the
Monte Carlo calculation (MCC) using the Mann–Whitney U-test. The dose was
measured three times, and is shown as mean ± the standard deviation.
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the gantry angles were 90° and 270°. We prescribed
200 cGy to 95% of the target ROI. This plan was calcu-
lated using the PBC algorithm first, and then recalcu-
lated using the MCC algorithm of the iPlan RT™
(version 4.1.2). The planned dose distributions were
compared using 3DVH software with the same gamma
criteria mentioned above. The gamma passing rates were
100%, 98.7%, and 98.8% for the target ROI, the periphery
ROI, and the entire area with the gamma 3%/3 mm criter-
ion. With the 2%/2 mm criterion, the gamma passing rates
were 100%, 96.6%, and 96.7%, respectively.
Reference measurements with ArcCHECK device were
also performed using the parallel-opposing static plan,
and these results were also analyzed using 3DVH soft-
ware and are shown in Table 1. The gamma passing
rates of the target ROI were 100% in both the PBC and
MCC even with the 2%/2 mm gamma criterion. How-
ever, the gamma passing rate of the periphery ROI were
94.2% in the PBC and 97.7% in the MCC with the 2%/
2 mm gamma criterion. The difference was statisticallyFigure 2 Comparison between the pencil-beam calculation dose distr
reference plan with static beams. The points that failed to satisfy the gasignificant (p = 0.046) according to the Mann–Whitney
U-test. The points that failed to satisfy the gamma cri-
teria (3%/3 mm and 2%/2 mm) are shown in Figure 2.
Comparison between the PBC and MCC dose distributions
in the arc plan
With the aid of 3DVH software, we directly compared
the PBC and MCC-calculated dose distribution. The 3D
gamma passing rates were 97.7%, 96.6% and 96.7% for the
target ROI, periphery ROI and the entire area with the
gamma 3%/3 mm criterion. The gamma passing rates
decreased to 86.9%, 89.2% and 89.0%, respectively, when
2%/2 mm criterion was used. The points that failed to
satisfy the gamma criteria (3%/3 mm and 2%/2 mm) are
shown in Figure 3.
Analysis of 2D gamma passing rates at the level of diodes
with ArcCHECK
The gamma passing rates at the level of diodes are
shown in Table 2. For the gamma 3%/3 mm criterion,
the gamma passing rates were 88.5% in PBC and 97.9%
in MCC. The gamma passing rates decreased to 72.1% in
PBC and 91.2% in MCC, when 2%/2 mm criterion was
applied. However, no matter which criterion was used,
the gamma passing rates at the level of diodes were sig-
nificantly higher in MCC compared to PBC (p < 0.05).
Analysis of 3D gamma passing rates with 3DVH
Table 3 shows the 3D gamma analysis results for each
ROI and the entire area, which were obtained by com-
paring the planned dose to the estimated dose using the
3DVH software. We compare these results between the
PBC and MCC algorithms. The gamma passing rate of
the entire area was 98.8% under the PBC algorithm and
100.0% under the MCC algorithm when the 3%/3 mm
gamma criterion was applied. Although both gamma pass-
ing rates were high, the gamma passing rate of the MCC
was statistically higher than that of the PBC (p = 0.034).
Furthermore the gamma passing rate decreases 7.5% inibution and the Monte Carlo calculation dose distribution of the
mma criteria (Left: 3%/3 mm, Right: 2%/2 mm) are shown.
Figure 3 Comparison between the pencil-beam calculation dose distribution and the Monte Carlo calculation dose distribution of the
arc plan. The points that failed to satisfy the gamma criteria (Left: 3%/3 mm, Right: 2%/2 mm) are shown.
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only a 0.4% decrease under the MCC algorithm. Not only
the entire area but also each ROI (target and periphery)
showed statistically significant higher gamma passing
rates under the MCC algorithm.
When we compare the accuracy between the target
ROI and the periphery ROI, the gamma passing rate of
the target ROI was lower than that of the periphery ROI
for all cases. The gamma passing rates of the periphery
ROI were 98.8% (PBC) and 100.0% (MCC) compared to
97.6% (PBC) and 99.8% (MCC) for the target ROI under
the gamma 3%/3 mm criterion. The gamma passing rates
of the periphery ROI were 91.9% (PBC) and 99.7% (MCC)
compared to 67.6% (PBC) and 96.2% (MCC) for the target
ROI under the gamma 2%/2 mm criterion.
Figures 4 and 5 show the points that failed to satisfy
the gamma criteria under the PBC and MCC algorithms,
respectively. In the PBC algorithm, the failure points are
distributed along the rim of the target. For the periphery
ROI, the failure points show a regular pattern repeated
every 10°. On the other hand, under the MCC algorithm,
only a few failure points are scattered in a random fash-
ion in both the target and periphery ROIs.
Comparison of DVH-based parameters
Table 4 shows the DVH-based parameters in absolute
dose, where one is obtained from the planned dose data
and the other is estimated by the 3DVH software basedTable 2 2D gamma analysis at the levels of diodes with
two gamma criteria (3%/3 mm and 2%/2 mm) in absolute
doses with a threshold of 5%
Gamma criteria
Gamma passing rate (%) p value
PBC plan MCC plan
3%/3 mm 88.50 ± 1.91 97.90 ± 1.21 0.043
2%/2 mm 72.07 ± 0.40 91.17 ± 0.12 0.046
Abbreviations: PBC Pencil-beam calculation, MCC Monte Carlo calculation.
The statistical significance between the pencil-beam calculation (PBC) and the
Monte Carlo calculation (MCC) is calculated with the Mann–Whitney U-test. The
dose was measured three times, and is shown as mean ± the standard deviation.on the ArcCHECK measurements. Table 5 shows the
dose deviation in percentage. The mean dose of the tar-
get ROI calculated by the PBC algorithm was 627 cGy,
similar to that of the 614 cGy estimated by the 3DVH
software. The mean dose of the target ROI calculated
by the MCC was 614 cGy, also similar to that of the
622 cGy estimated by the 3DVH software. The dose
deviation was 2% in the PBC and 1% in the MCC with
respect to the mean dose. Of the six DVH parameters
evaluated in this study, four parameters (mean dose,
D99, D90, and D50) showed better accuracy in the MCC
than in the PBC in both the target and periphery ROI. On
the other hand, for the maximal dose of both ROIs and
for the D1 dose of the target ROI, the PBC algorithm
showed better agreement.
In every DVH-based parameter, the dose deviation was
below 10% both under the PBC and the MCC algorithm.
Dose deviations higher than 5% were only observed in
D90 and D1 of the periphery ROI calculated by the PBC
algorithm (Table 5).
Figure 6 shows the real DVH, comparing the planned
dose and the estimated dose. Although no significant dif-
ferences can be found in several parameters when com-
paring the PBC and the MCC, the DVH lines showed
better agreement in the MCC algorithm compared to the
PBC for both ROIs.
Discussion
Rotational arc therapy has recently been receiving a great
deal of attention because of the possibility of acquiring a
plan with improved dose distribution, shorter treatment
time, and small MU in certain treatment sites. Shepard
et al. demonstrated the dosimetric benefits of rotational
treatments by summarizing results from an optimization
series performed for a C-shaped target [23]. The result
showed that each increase in the number of beam angles
led to a more homogenous dose in the target and a lower
dose to the adjacent structure. The total integral dose was
independent of the number of angles. Based on these
Table 3 3D gamma analysis with two gamma criteria
(3%/3 mm and 2%/2 mm) in absolute doses with a
threshold of 5%
Gamma 3%/3 mm
Gamma passing rate (%)
p value
PBC MCC
Target ROI 97.60 ± 0.36 99.80 ± 0.00 0.037
Periphery ROI 98.83 ± 0.06 100.00 ± 0.00 0.034
Entire area 98.83 ± 0.06 100.00 ± 0.00 0.034
Gamma 2%/2 mm PBC MCC p value
Target ROI 67.57 ± 1.50 96.20 ± 0.06 0.034
Periphery ROI 91.97 ± 0.12 99.70 ± 0.00 0.034
Entire area 91.30 ± 0.17 99.60 ± 0.00 0.034
Abbreviations: PBC Pencil-beam calculation, MCC Monte Carlo calculation.
The 3D gamma passing rate of the entire area and of each region of interest
(target and periphery ROI) are compared between the pencil-beam calculation
(PBC) and the Monte Carlo calculation (MCC) with the Mann–Whitney U-test.
The dose was measured three times, and is shown as mean ± the
standard deviation.
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to achieve more conformal 3D dose distributions in
recent years, such as IMAT, helical tomotherapy and
VMAT [1-3]. To use these techniques in clinical prac-
tice, the accuracy of the planning algorithm and QA
tools are essential.
The usefulness of ArcCHECK, the 3D volumetric diode
dosimeter used in this study, has already been validated by
other investigators [11,12,14,17,24]. Li et al. performed
several tests for the ArcCHECK QA system, and evalu-
ated the suitability of this system for IMRT and VMAT
verification [11]. The short term reproducibility, the
dose linearity, the dose rate dependence, the dose per
pulse dependence, the field size dependence and the outFigure 4 The points that failed to satisfy the gamma criteria of 2%/2
distribution of the plan calculated by the pencil-beam calculation algorithm
(using the 3DVH software based on the measurements) is shown in the lowof field dependence were very good, and were satisfied
in the clinical QA conditions. Neilson et al. evaluated
the accuracy and usefulness of ArcCHECK device with
169 delivery QA plans from 84 patients treated by
Hi-ART Tomotherapy [12]. They concluded the Arc-
CHECK can save resources and provide accurate delivery
QA results compared to the QA methods with radio-
graphic film and ion-chamber. Based on these several
studies, we incorporated the ArcCHECK QA system for
this rotational arc therapy study.
Most commonly used TPSs calculate the dose by
evenly dividing the rotating irradiation angles into mul-
tiple fields to simulate an arc. The PBC algorithm of the
iPlan RT TPS divided the angles into 10° segments [5].
On the other hand, the MCC algorithm basically relies
on random sampling and integration [25]. The MCC
algorithm of the iPlan RT TPS is based on the XVMC
code, which consists of three main components: a virtual
energy fluence model [26], a full MC geometry simulation
of the photon transport [27], and a patient dose computa-
tion [19,20]. Several studies have tested and validated the
MCC algorithm of the iPlan RT TPS [6,10].
The accuracy of the MCC compared to the PBC has
been reported in many studies [5-10]. However, the
comparisons of the MCC and PBC in arc therapy has
been limited, and have usually only focused on the
discrepancy under inhomogeneous conditions [5,6]. Our
result demonstrates that the MCC showed better accuracy
than the PBC in an arc plan even under homogenous
conditions. When we directly compared the dose distri-
butions of the PBC with those of the MCC, the degree
of agreement was only 89% for the entire area as deter-
mined by 2%/2 mm gamma analysis. This is despite themm under the pencil-beam calculation algorithm (left). The dose
is shown in upper right field, and the reconstructed dose distribution
er right field.
Figure 5 The points that failed to satisfy the gamma criteria of 2%/2 mm under the Monte Carlo calculation algorithm (left). The dose
distribution of the plan calculated by the Monte Carlo calculation algorithm is shown in upper right field, and the reconstructed dose distribution
(using the 3DVH software based on the measurements) is shown in the lower right field.
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algorithms. This result demonstrates the discrepancy
between the two algorithms.
The result of the 2D gamma analysis with ArcCHECK
showed that the MCC dose distribution was in better
agreement with the measurement than the PBC. The
gamma passing rate of the MCC was 19.1% higher than
that of the PBC at the levels of ArcCHECK diodes with
a 2%/2 mm gamma criterion. With the aid of the 3DVH










Max dose 639 630 62
Mean dose 627 614 11
D99 591 571 8
D90 615 595 12
D50 630 619 10
D1 638 629 51





Max dose 670 646 65
Mean dose 614 622 10
D99 572 588 8
D90 596 603 13
D50 619 627 10
D1 630 640 48
Abbreviations: PBC Pencil-beam calculation, MCC Monte Carlo calculation, ROI region
the volume, D50 dose covering 50% of the volume, D1 dose covering 1% of the vo
The estimated dose is calculated based on the ArcCHECK measured data.gamma passing rate was statistically higher in the MCC
compared with that in the PBC not only for the entire
area, but also for each ROI. The gamma passing rate
was 99.8-100% for the MCC compared to 97.6-98.8% for
the PBC for a 3%/3 mm gamma analysis. The difference
was more prominent when a more stringent gamma cri-
terion (2%/2 mm) was used. Using 2%/2 mm gamma
analysis, the gamma passing rate was 96.2-99.7% for the
MCC compared with 67.6-91.9% for the PBC. With
these results, we can draw the conclusion that the MCCained from the plan and with those estimated by the
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5 628 670 646
9 109 119 119
8 8 8
13 13 13
7 106 110 109
3 488 618 626
of interest, D99 dose covering 99% of the volume, D90 dose covering 90% of
lume.
Table 5 A comparison of the dose deviations (%) of six
DVH-based dose parameters obtained from the plan and
with those estimated by the 3DVH software
Dose
deviation
Target ROI Periphery ROI Entire area
PBC MCC PBC MCC PBC MCC
Max dose 1% 4% 1% 4% 1% 4%
Mean dose 2% 1% 4% 0% 4% 0%
D99 3% 1% 0% 0% 0% 0%
D90 3% 1% 8% 0% 8% 0%
D50 2% 1% 2% 1% 1% 1%
D1 1% 2% 6% 1% 2% 1%
Abbreviations: PBC Pencil-beam calculation, MCC Monte Carlo calculation, ROI
region of interest, D99 dose covering 99% of the volume, D90 dose covering
90% of the volume, D50 dose covering 50% of the volume, D1 dose covering
1% of the volume.
The estimated dose is calculated based on the ArcCHECK measured data.
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under homogenous conditions.
The points that failed the gamma criteria in the PBC
showed a regular pattern. In the target, the points are
distributed at the rim. In the periphery ROI, the points
are scattered and repeated at 10° intervals. However,
only a few points are scattered in an irregular pattern in
the MCC. The patterns observed in our study suggest
that the accuracy of the PBC algorithm of iPlan RT is
inferior compared with that of the MCC algorithm be-
cause of the discretization of the continuous arc, which
results in the effective usage of several beams to simu-
late an arc. To increase the dose distribution accuracy
of the PBC, it seems necessary to increase the number
of discrete beams for the dose calculation [5]. However,
increasing the number of beams will lead to a longerFigure 6 The dose-volume histograms comparing the plan dose and
distribution (thick line) vs. 3DVH estimation (thin line), (Right) Monte Carlo c
(thin line).calculation time; for MCC, there is no increase in the
calculation time, which can be an inherent advantage of
the MCC for arc therapy.
Some precautions must be taken when interpreting
our results. First, the magnitude of the discrepancy was
not entirely due to discretizing the arc. The reference
study with static beams also showed some dose differ-
ences between the PBC and MCC algorithms. The de-
gree of agreement between the two dose distributions
was determined to be 96.7% for the entire area by means
of a 2%/2 mm gamma analysis, for which the errors were
observed only in the periphery ROI, and more specific-
ally in the field margin (Figure 2). Based on the Arc-
CHECK measurement result of the reference study with
static beams, we were able to determine that the field
margin errors were also from the PBC algorithm because
the measurement agreed better with the MCC dose dis-
tribution. Although statistically significant differences
existed even in the reference study with static beams,
the magnitude of the dose difference between the PBC
and MCC was much larger in the arc therapy plan
(11.0% for the entire area as determined through a 2%/
2 mm gamma analysis) compared to the reference plan
(3.3% for the entire area as determined through a 2%/
2 mm gamma analysis).
Second, this result was based only on the iPlan RT TPS.
Therefore, the result of our study should not be general-
ized to other arc therapy TPSs. For example, Tudor et al.
reported that with 51 calculation angles, a dose difference
greater than 1% was absent in the Tomotherapy plans
studied when the number of calculation angles was in-
creased by a factor of 5 or more [28].
In a study of Petoukhova et al., the authors measured
several clinical HybridArc plans (iPlan RT TPS) with anthe 3DVH estimated dose. (Left) Pencil-beam calculation (PBC) dose
alculation (MCC) dose distribution (thick line) vs. 3DVH estimation
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PBC significantly differed from the ArcCHECK measure-
ments [9]. The gamma passing rate with a 2%/2 mm criter-
ion was 61.5-77.8% in the PBC compared to 91.8-97.5% in
the MCC. They also demonstrated points with more than a
2% dose difference. These points were distributed not only
in the low-dose region but also within the target, as in
our study. However, they could not find a regular pattern
among these points, which may be due to the different
treatment technique that they used.
In our study, we used the 3DVH software to obtain the
3D gamma passing rate results not only for the entire
area but also for each ROIs. Another great advantage of
the 3DVH software is that several DVH-based parame-
ters can be estimated based on the measured data, and
can be compared to that of the plan data. The details of
the algorithm and validation of its accuracy have been
reported in several reports [12,18,21,22]. Through this
process we can obtain information about how the gamma
analysis is incorporated into clinical parameters. In our
study, it was difficult to find any correlation between
the gamma passing rates and the several DVH-based
parameters. Although the target ROI gamma passing
rate decreases to 67.6% under the PBC algorithm with
gamma 2%/2 mm, the dose deviations of all the DVH
parameters of the target ROI were just 1-3%. On the
other hand, two parameters (D90 and D1) showed
more than a 5% dose deviation in the periphery ROI
in spite of the 92.0% gamma passing rate. Although it
was difficult to draw a conclusion from our study of
the correlation between the gamma analysis and several
DVH-based parameters, that was also not the aim of this
study, and the lack of correlation of the gamma analysis
with any of several DVH-based parameters has been
demonstrated in several other reports [17,18,21,29]
Through this study, we have also learned that delivery
QA using ArcCHECK and 3DVH software can provide
physicians with a great deal of information through a
simple and easy procedure, although it remains difficult
to suggest specific guidelines, and this question is be-
yond the scope of this paper.
What is clear in our study is that the MCC showed
better accuracy than the PBC of iPlan RT TPS in calcu-
lating the dose distribution in arc therapy, which was
validated with the ArcCHECK measurement and the
3DVH software. This may suggest that the arc step of 10°
is too large in the PBC algorithm in the iPlan RT TPS.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SHS, CSK, and SMC performed the experiment design. SHS and HJS
performed data collection. HJS performed the treatment planning and
conducted all planning evaluation. JHS and SHS interpreted the data. SHSperformed the statistical analysis. JHS drafted the manuscript. All authors
read and approved the final manuscript.Acknowledgements
The authors wish to acknowledge the financial support of the Catholic
Medical Center Research Foundation made in the program year of 2011
(5-2011-B0001-00196).
Author details
1Department of Radiation Oncology, Seoul St. Mary’s hospital, College of
Medicine, The Catholic University of Korea, Seoul, Korea. 2Department of
Radiation Oncology, Incheon St. Mary’s hospital, College of Medicine, The
Catholic University of Korea, Incheon, Korea. 3Department of Radiation
Oncology, Cheju Halla General Hospital, Jeju, Korea.
Received: 23 April 2013 Accepted: 24 November 2013
Published: 5 December 2013References
1. Feygelman V, Zhang G, Stevens C, Nelms BE: Evaluation of a new VMAT
QA device, or the “X” and “O” array geometries. J Appl Clin Med Phys
2011, 12:3346.
2. Shepard DM, Cao D, Afghan MK, Earl MA: An arc-sequencing algorithm for
intensity modulated arc therapy. Med Phys 2007, 34:464–470.
3. Yu CX, Tang G: Intensity-modulated arc therapy: principles, technologies
and clinical implementation. Phys Med Biol 2011, 56:R31–R54.
4. Morales-Paliza MA, Coffey CW, Ding GX: Evaluation of the dynamic
conformal arc therapy in comparison to intensity-modulated radiation
therapy in prostate, brain, head-and-neck and spine tumors. J Appl Clin
Med Phys 2011, 12:3197.
5. Chow JC, Wong E, Chen JZ, Van Dyk J: Comparison of dose calculation
algorithms with Monte Carlo methods for photon arcs. Med Phys 2003,
30:2686–2694.
6. Petoukhova AL, van Wingerden K, Wiggenraad RG, van de Vaart PJ, van
Egmond J, Franken EM, van Santvoort JP: Verification measurements and
clinical evaluation of the iPlan RT Monte Carlo dose algorithm for 6 MV
photon energy. Phys Med Biol 2010, 55:4601–4614.
7. Garnica-Garza HM: A monte carlo comparison of three different media for
contrast enhanced radiotherapy of the prostate. Technol Cancer Res Treat
2010, 9:271–278.
8. Krieger T, Sauer OA: Monte Carlo- versus pencil-beam-/collapsed-cone-
dose calculation in a heterogeneous multi-layer phantom. Phys Med Biol
2005, 50:859–868.
9. Petoukhova AL, van Egmond J, Eenink MG, Wiggenraad RG, van Santvoort JP:
The ArcCHECK diode array for dosimetric verification of HybridArc. Phys
Med Biol 2011, 56:5411–5428.
10. Fragoso M, Wen N, Kumar S, Liu D, Ryu S, Movsas B, Munther A, Chetty IJ:
Dosimetric verification and clinical evaluation of a new commercially
available Monte Carlo-based dose algorithm for application in
stereotactic body radiation therapy (SBRT) treatment planning. Phys Med
Biol 2010, 55:4445–4464.
11. Li G, Zhang Y, Jiang X, Bai S, Peng G, Wu K, Jiang Q: Evaluation of the
ArcCHECK QA system for IMRT and VMAT verification. Phys Med 2013,
29:295–303.
12. Neilson C, Klein M, Barnett R, Yartsev S: Delivery quality assurance with
ArcCHECK. Med Dosim 2013, 38:77–80.
13. Bedford JL, Lee YK, Wai P, South CP, Warrington AP: Evaluation of the
Delta4 phantom for IMRT and VMAT verification. Phys Med Biol 2009,
54:N167–N176.
14. Yan G, Lu B, Kozelka J, Liu C, Li JG: Calibration of a novel four-dimensional
diode array. Med Phys 2010, 37:108–115.
15. Low DA, Harms WB, Mutic S, Purdy JA: A technique for the quantitative
evaluation of dose distributions. Med Phys 1998, 25:656–661.
16. Ezzell GA, Burmeister JW, Dogan N, LoSasso TJ, Mechalakos JG, Mihailidis D,
Molineu A, Palta JR, Ramsey CR, Salter BJ, et al: IMRT commissioning:
multiple institution planning and dosimetry comparisons, a report from
AAPM Task Group 119. Med Phys 2009, 36:5359–5373.
17. Nelms BE, Opp D, Robinson J, Wolf TK, Zhang G, Moros E, Feygelman V:
VMAT QA: measurement-guided 4D dose reconstruction on a patient.
Med Phys 2012, 39:4228–4238.
Song et al. Radiation Oncology 2013, 8:284 Page 11 of 11
http://www.ro-journal.com/content/8/1/28418. Olch AJ: Evaluation of the accuracy of 3DVH software estimates of dose
to virtual ion chamber and film in composite IMRT QA. Med Phys 2012,
39:81–86.
19. Fippel M: Fast Monte Carlo dose calculation for photon beams based on
the VMC electron algorithm. Med Phys 1999, 26:1466–1475.
20. Kawrakow I, Fippel M, Friedrich K: 3D electron dose calculation using a
Voxel based Monte Carlo algorithm (VMC). Med Phys 1996, 23:445–457.
21. Carrasco P, Jornet N, Latorre A, Eudaldo T, Ruiz A, Ribas M: 3D DVH-based
metric analysis versus per-beam planar analysis in IMRT pretreatment
verification. Med Phys 2012, 39:5040–5049.
22. Zhen H, Nelms BE, Tome WA: Moving from gamma passing rates to
patient DVH-based QA metrics in pretreatment dose QA. Med Phys 2011,
38:5477–5489.
23. Shepard DM, Olivera G, Angelos L, Sauer O, Reckwerdt P, Mackie TR: A
simple model for examining issues in radiotherapy optimization. Med Phys
1999, 26:1212–1221.
24. Kozelka J, Robinson J, Nelms B, Zhang G, Savitskij D, Feygelman V:
Optimizing the accuracy of a helical diode array dosimeter: a
comprehensive calibration methodology coupled with a novel virtual
inclinometer. Med Phys 2011, 38:5021–5032.
25. Jabbari K: Review of fast monte carlo codes for dose calculation in
radiation therapy treatment planning. J Med Signals Sens 2011, 1:73–86.
26. Fippel M, Haryanto F, Dohm O, Nusslin F, Kriesen S: A virtual photon
energy fluence model for Monte Carlo dose calculation. Med Phys 2003,
30:301–311.
27. Fippel M: Efficient particle transport simulation through beam
modulating devices for Monte Carlo treatment planning. Med Phys 2004,
31:1235–1242.
28. Tudor GS, Thomas SJ: Impact of the fixed gantry angle approximation on
dosimetric accuracy for helical tomotherapy plans. Med Phys 2013,
40:011711.
29. Stasi M, Bresciani S, Miranti A, Maggio A, Sapino V, Gabriele P: Pretreatment
patient-specific IMRT quality assurance: a correlation study between
gamma index and patient clinical dose volume histogram. Med Phys
2012, 39:7626–7634.
doi:10.1186/1748-717X-8-284
Cite this article as: Song et al.: Comparison of dose calculations
between pencil-beam and Monte Carlo algorithms of the iPlan RT in
arc therapy using a homogenous phantom with 3DVH software.
Radiation Oncology 2013 8:284.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
